PR Newswire Clinical TrialsOriginal article
Hansa Biopharma announces closing of €115 million licensing transaction with SERB Pharmaceuticals for Idefirix in Europe and MENA
PartnershipIdefirixPositive
AI Analysis
Summary
Hansa Biopharma closed a €115 million licensing transaction with SERB Pharmaceuticals, granting SERB commercialization rights for Idefirix in Europe, MENA, and select other regions. The deal strengthens Hansa's financial position and supports its planned US launch pending regulatory approval.
Financial Highlights
Revenue
€115 million
Outcome Details
Licensing transaction closed for €115 million; SERB assumes commercialization rights in EU, UK, Switzerland, Norway, Liechtenstein, Iceland, and MENA region
Importance:7/10
Sentiment:
0.70
licensingpartnershipcommercializationgeographic expansionIdefirix
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on July 1, 2026 1:24 PM